Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Depreciation and Depletion (2019 - 2025)

Historic Depreciation and Depletion for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $400000.0.

  • Pliant Therapeutics' Depreciation and Depletion fell 2000.0% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 1854.92%. This contributed to the annual value of $2.1 million for FY2024, which is 1542.64% up from last year.
  • Per Pliant Therapeutics' latest filing, its Depreciation and Depletion stood at $400000.0 for Q3 2025, which was down 2000.0% from $400000.0 recorded in Q2 2025.
  • Over the past 5 years, Pliant Therapeutics' Depreciation and Depletion peaked at $600000.0 during Q2 2024, and registered a low of $400000.0 during Q1 2021.
  • In the last 5 years, Pliant Therapeutics' Depreciation and Depletion had a median value of $425000.0 in 2024 and averaged $450947.4.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 5000.0% in 2024, then tumbled by 3333.33% in 2025.
  • Over the past 5 years, Pliant Therapeutics' Depreciation and Depletion (Quarter) stood at $418000.0 in 2021, then increased by 1.2% to $423000.0 in 2022, then increased by 4.26% to $441000.0 in 2023, then decreased by 3.63% to $425000.0 in 2024, then decreased by 5.88% to $400000.0 in 2025.
  • Its Depreciation and Depletion was $400000.0 in Q3 2025, compared to $400000.0 in Q2 2025 and $448000.0 in Q1 2025.